ImmVue Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $4M

  • Investors
  • 1

ImmVue Therapeutics General Information

Description

Developer of a small-molecule-based therapeutic platform designed to modulate cell activities through allosteric modulation. The company's platform offers allosteric agonists and inhibitors of interleukin-2-inducible T-cell kinase and Bruton's tyrosine kinase, enabling patients with enhanced immune response against treatment-resistant cancers.

Contact Information

Website
www.immvue.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 College Street
  • Suite 200
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (416)
Primary Industry
Biotechnology
Corporate Office
  • 101 College Street
  • Suite 200
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (416)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmVue Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 19-Mar-2025 $4M Completed Startup
1. Seed Round 01-Aug-2021 Completed Stealth
To view ImmVue Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ImmVue Therapeutics Patents

ImmVue Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025230982-A1 Itk-ph domain inhibitors and their uses Pending 30-Apr-2024
WO-2025230998-A1 Tec kinase agonists and their use in enhancing lymphocyte activation Pending 30-Apr-2024

ImmVue Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmVue Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Novatio Ventures Venture Capital Minority
To view ImmVue Therapeutics’s complete investors history, request access »

ImmVue Therapeutics FAQs

  • When was ImmVue Therapeutics founded?

    ImmVue Therapeutics was founded in 2017.

  • Where is ImmVue Therapeutics headquartered?

    ImmVue Therapeutics is headquartered in Toronto, Canada.

  • What is the size of ImmVue Therapeutics?

    ImmVue Therapeutics has 6 total employees.

  • What industry is ImmVue Therapeutics in?

    ImmVue Therapeutics’s primary industry is Biotechnology.

  • Is ImmVue Therapeutics a private or public company?

    ImmVue Therapeutics is a Private company.

  • What is ImmVue Therapeutics’s current revenue?

    The current revenue for ImmVue Therapeutics is .

  • How much funding has ImmVue Therapeutics raised over time?

    ImmVue Therapeutics has raised $5.6M.

  • Who are ImmVue Therapeutics’s investors?

    Novatio Ventures has invested in ImmVue Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process